GeneReach Biotechnology (4171) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GeneReach Biotechnology (4171) has a cash flow conversion efficiency ratio of 0.020x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$12.05 Million ≈ $379.64K USD) by net assets (NT$596.72 Million ≈ $18.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of GeneReach Biotechnology to measure how much of total assets are equity-financed.
GeneReach Biotechnology - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how GeneReach Biotechnology's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check GeneReach Biotechnology earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
GeneReach Biotechnology Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GeneReach Biotechnology ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gabriel Resources Ltd
V:GBU
|
0.080x |
|
Genoway
PA:ALGEN
|
-0.152x |
|
Battalion Oil Corp
NYSE MKT:BATL
|
-1.381x |
|
Unifin Financiera S. A. B. de C. V
MX:UNIFINA
|
-0.199x |
|
Malmbergs Elektriska AB (publ)
ST:MEAB-B
|
-0.016x |
|
TINYBUILD REGSCAT3 DL-001
F:8Z3
|
N/A |
|
Tycoons Worldwide Group (Thailand) Public Company Limited
BK:TYCN
|
-0.050x |
|
Systech Bhd
KLSE:0050
|
1.187x |
Annual Cash Flow Conversion Efficiency for GeneReach Biotechnology (2017–2025)
The table below shows the annual cash flow conversion efficiency of GeneReach Biotechnology from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see GeneReach Biotechnology (4171) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$596.72 Million ≈ $18.80 Million |
NT$-13.52 Million ≈ $-425.80K |
-0.023x | +29.25% |
| 2024-12-31 | NT$725.49 Million ≈ $22.86 Million |
NT$-23.22 Million ≈ $-731.68K |
-0.032x | +28.61% |
| 2023-12-31 | NT$862.44 Million ≈ $27.17 Million |
NT$-38.67 Million ≈ $-1.22 Million |
-0.045x | -113.83% |
| 2022-12-31 | NT$1.10 Billion ≈ $34.74 Million |
NT$357.63 Million ≈ $11.27 Million |
0.324x | +1.12% |
| 2021-12-31 | NT$1.09 Billion ≈ $34.28 Million |
NT$348.99 Million ≈ $11.00 Million |
0.321x | +62.01% |
| 2020-12-31 | NT$857.76 Million ≈ $27.02 Million |
NT$169.82 Million ≈ $5.35 Million |
0.198x | +1148.98% |
| 2019-12-31 | NT$593.05 Million ≈ $18.68 Million |
NT$-11.19 Million ≈ $-352.64K |
-0.019x | -202.24% |
| 2018-12-31 | NT$311.15 Million ≈ $9.80 Million |
NT$5.74 Million ≈ $180.97K |
0.018x | +167.78% |
| 2017-12-31 | NT$250.63 Million ≈ $7.90 Million |
NT$-6.83 Million ≈ $-215.06K |
-0.027x | -- |
About GeneReach Biotechnology
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers various equipment, such as POCKIT Central Nucleic Acid Analyzer, POCKIT Micro Series, taco mini Automatic Nucleic Acid Extraction System, taco Prep Homogenization System, and cubee Mini-Centrifuge; reagents and consumables, including Human IVD Assa… Read more